Where
Bengaluru International Exhibition Centre, Bengaluru
When
15-17 February, 2018
Inauguration of Exhibition & Media Interaction
Inauguration of Exhibition & Media Interaction - India Pharma & India Medical Device by Hon’ble Minister along with visit to the Exhibition with Dignitaries. Exhibition will be open from 10 am to 6 pm for Business Visitors
INDIA PHARMA: Discovering Innovative Medicines in India: NCE Research – India Perspective
INDIA PHARMA CEO's Roundtable
INDIA PHARMA CEO's Roundtable with Hon'ble Minister for Chemicals & Fertilizers, Ministry of Chemicals & Fertilizers. Govt. of India (By Invitation
Domestic Context and Global Scenario
INDIA PHARMA: Opportunities, Challenges and Regulatory Requirements in the Development of Biologics – Domestic Context and Global Scenario
Joint International Regulators Interaction with CEOs Pharmaceuticals Medical Device
Hosted Buyer seller Meet at BIEC, Hall 3(Pre-fixed B2B meetings)
Exhibition
Joint International Regulators Meet
Joint International Regulators Meet: Session on Sharing International Best Practices and Ensuring Quality in line with Global Standards for Pharmaceuticals & Medical Device sector
Workshop by WHO
Workshop by WHO: Regulatory System Strengthening and Prequalification updated by WHO
INDIA PHARMA-Technical Session-Opportunities & Challenges for Stem cells & Regenerative medicine
public healthcare system
INDIA PHARMA: Emerging global trends in Self Care and relevance of OTC regulatory framework for Indian public healthcare system
Exhibition & Buyer Seller Meet
Roundtable Discussion
IQVIA Workshop on EU & APAC medical device REGULATIONS and Roundtable on Medical Device Rules 2018
Workshop by NASSCOM
Workshop by NASSCOM: Digital Transformation through Innovation in Pharmaceutical, Medical Devices and Healthcare Industries
The Indian pharmaceutical industry has contributed immensely not just to Indian but to global
healthcare outcomes. India continues to play a material role in manufacturing various critical, high-quality and low‐cost medicines for Indian and global markets. It supplies 50 to 60 percent of global demand for many vaccines (including ARVs), 40 percent of generics consumed in the US and 25 percent of all the medicines dispensed in the UK. Over the last 5 years, 35 to 38 percent of total ANDAs approved (including 25 to 30 percent of total injectable ANDAs) have been filed from Indian sites. Affordable anti‐retroviral (ARV) drugs from India were a major factor in AIDS patients getting greater access to treatment. India supplies 60 percent of global ARV drugs and 30 percent of the annual UNICEF requirement.
However, over the last few quarters many Indian pharmaceutical companies (like other global peers) have registered much lower growth and profitability. Many have experienced significant value erosion, which to a large extent has posed a hindrance to industry’s capacity expansion and R&D plans.
Address
Bengaluru International Exhibition Centre, Bengaluru
Email us
swati.aggarwal@ficci.com
Call us
+91-11-2348 7409
+91-11-2348 7355
